Option Care Health, Inc.

28.67+0.47 (+1.67%)

Oct 29, 4:00:00 PM EDT · NasdaqGS · OPCH · USD

Upcoming Earnings

Report date

Key Stats

Market Cap

4.65B

P/E (TTM)

22.75

Basic EPS (TTM)

1.26

Dividend Yield

Recent Filings

8-K

CFO Transition Announced

8/20/25Aug 20, 2025

Option Care Health appointed Meenal Sethna as EVP and CFO effective October 1, 2025, succeeding Mike Shapiro, who steps down after a decade but stays on as special advisor through March 31, 2026. Sethna brings 30 years of finance experience from Littelfuse and Illinois Tool Works, with a $655,000 base salary, 90% target bonus, and $2.4 million annual equity target, plus a $1.5 million sign-on RSU. Shapiro's pay drops to $246,000 during transition. This leadership shift bolsters financial strategy amid strong momentum.

10-Q

Q2 FY2025 results

7/30/25Jul 30, 2025

Option Care Health posted solid Q2 revenue of $1.4B, up 15.4% year-over-year and 8.7% quarter-over-quarter (derived), fueled by mid-teens organic growth in acute and chronic therapies amid shifting competition, though gross margins dipped to 19.0% from 20.3% due to pricier rare disease mixes and slimmer procurement spreads. Operating income rose 2.5% y/y to $82.7M, with diluted EPS steady at $0.31 on 164M shares, reconciling cleanly without dilution flags. The January 2025 Intramed Plus buyout closed for $117.2M cash, adding $65.6M goodwill and $45.1M intangibles amortized over 15 years for procurement synergies. Cash fell to $198.8M after $83.1M operating inflows minus $18.5M capex and $150M buybacks, yet $395.9M revolver availability bolsters liquidity against $1.1B debt at blended 5.5% rates. Acquisitions expand reach smartly. Reimbursement tweaks from payers pose ongoing pressure.

8-K

Q2 revenue surges 15.4%

7/30/25Jul 30, 2025

Option Care Health reported Q2 2025 net revenue of $1,416.1 million, up 15.4% from $1,227.2 million last year, while gross profit rose 7.9% to $269.0 million despite a dip to 19.0% margin. Net income edged down to $50.5 million from $53.0 million, but adjusted EBITDA climbed 5.2% to $114.0 million. The company repurchased $50.0 million in stock. It raised full-year guidance to $5.50-$5.65 billion in revenue, signaling resilience amid market pressures.

8-K

Governance amendments approved

5/16/25May 16, 2025

Option Care Health stockholders approved key governance updates at the May 14, 2025 annual meeting, including amendments to the certificate of incorporation granting certain shareholders the right to call special meetings, limiting officer liability under Delaware law, and removing outdated HC Group provisions. All eleven director nominees were elected with strong support, KPMG LLP was ratified as auditors, and executive compensation received advisory approval. These changes streamline operations while enhancing stockholder engagement. Governance evolves swiftly.

10-Q

Q1 FY2025 results

4/29/25Apr 29, 2025

Option Care Health posted solid Q1 results, with net revenue climbing 16.3% year-over-year to $1.33B, fueled by mid-teens growth in acute therapies and high-teens gains in chronic ones, though gross margin dipped to 19.7% from 20.8% on higher-cost rare therapies and procurement spread pressures. Operating income rose 14.8% to $79.2M, while diluted EPS held steady at $0.28 on 166.8M shares, reconciling cleanly with net income of $46.7M. The company closed its Intramed Plus acquisition in January 2025 for $117.3M net cash, adding $65.7M goodwill and $45.1M in finite-lived intangibles amortized over 15 years, targeting procurement synergies. Cash dipped to $171.4M after the deal and $100M stock buybacks, yet revolver availability stands at $395.9M against $1.1B debt. Free cash flow not disclosed in the 10-Q. Yet regulatory shifts in government reimbursements pose ongoing hurdles.

About

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

CEO

Mr. John C. Rademacher

IPO

8/15/1996

Website

https://www.optioncarehealth.com

Employees

8,000

Sector

Healthcare

Industry

Medical Care Facilities